Ocugen, Inc. (OCGN)
NASDAQ: OCGN · Real-Time Price · USD
1.395
-0.015 (-1.06%)
Feb 12, 2026, 1:17 PM EST - Market open
Ocugen Employees
Ocugen had 95 employees as of December 31, 2024. The number of employees increased by 30 or 46.15% compared to the previous year.
Employees
95
Change (1Y)
30
Growth (1Y)
46.15%
Revenue / Employee
$56,526
Profits / Employee
-$673,895
Market Cap
457.40M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 95 | 30 | 46.15% |
| Dec 31, 2023 | 65 | -19 | -22.62% |
| Dec 31, 2022 | 84 | 28 | 50.00% |
| Dec 31, 2021 | 56 | 41 | 273.33% |
| Dec 31, 2020 | 15 | -1 | -6.25% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| ADC Therapeutics | 265 |
| 4D Molecular Therapeutics | 227 |
| Prothena Corporation | 163 |
| Kyverna Therapeutics | 129 |
| Neumora Therapeutics | 95 |
| Verastem | 78 |
| Lineage Cell Therapeutics | 77 |
| Zevra Therapeutics | 59 |
OCGN News
- 3 days ago - Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer - GlobeNewsWire
- 20 days ago - Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock - GlobeNewsWire
- 21 days ago - Ocugen (OCGN) Stock Tumbles After $22.5 Million Share Offering - Benzinga
- 22 days ago - Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock - GlobeNewsWire
- 27 days ago - Ocugen, Inc. (OCGN) Discusses OCU410 Phase 2 ArMaDa Trial Data and Clinical Update for Geographic Atrophy Transcript - Seeking Alpha
- 4 weeks ago - Ocugen's Early Gene Therapy Data Shows 46% Drop In Vision Damage - Benzinga
- 4 weeks ago - Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration - GlobeNewsWire
- 4 weeks ago - Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data - GlobeNewsWire